{
    "info": {
        "nct_id": "NCT06103682",
        "official_title": "LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)",
        "inclusion_criteria": "1. Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies:\n\n   1. Cohort A: Non-small cell cancer\n   2. Cohort B: Small cell cancer\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. [Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "1. Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies:",
            "criterions": [
                {
                    "exact_snippets": "Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies",
                    "criterion": "genitourinary malignancies",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": [
                                "histologically",
                                "biochemically"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Cohort A: Non-small cell cancer",
            "criterions": [
                {
                    "exact_snippets": "Non-small cell cancer",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "non-small cell"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Cohort B: Small cell cancer",
            "criterions": [
                {
                    "exact_snippets": "Small cell cancer",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "small cell"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Provision of signed and dated informed consent form.",
            "criterions": [
                {
                    "exact_snippets": "Provision of signed and dated informed consent form.",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Stated willingness to comply with all study procedures and availability for the duration of the study.",
            "criterions": [
                {
                    "exact_snippets": "Stated willingness to comply with all study procedures",
                    "criterion": "willingness to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "availability for the duration of the study",
                    "criterion": "availability for the duration of the study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Age ≥18 years at time of consent.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.",
            "criterions": [
                {
                    "exact_snippets": "Currently on systemic therapy",
                    "criterion": "systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a candidate to continue their current line of systemic therapy",
                    "criterion": "continuation of systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no more than a planned 30-day break",
                    "criterion": "planned break from systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. [Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment]",
            "criterions": [
                {
                    "exact_snippets": "≥ 1 line of systemic therapy for metastatic disease",
                    "criterion": "systemic therapy for metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 3 months of clinical benefit on most recent line of systemic therapy",
                    "criterion": "clinical benefit on most recent line of systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to the development of new metastatic lesions",
                    "criterion": "development of new metastatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior"
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment",
                    "criterion": "tumor burden stability",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not requiring an immediate change in systemic treatment",
                    "criterion": "immediate change in systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. ≤ 5 progressing or new metastatic lesions.",
            "criterions": [
                {
                    "exact_snippets": "≤ 5 progressing or new metastatic lesions",
                    "criterion": "metastatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "progressing",
                                "new"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.",
            "criterions": [
                {
                    "exact_snippets": "All progressing or new metastatic lesions",
                    "criterion": "metastatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": [
                                "progressing",
                                "new"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "can be safely treated with locally ablative therapies",
                    "criterion": "treatability with locally ablative therapies",
                    "requirements": [
                        {
                            "requirement_type": "safety",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "1. Medical comorbidities precluding locally ablative therapies.",
            "criterions": [
                {
                    "exact_snippets": "Medical comorbidities precluding locally ablative therapies",
                    "criterion": "medical comorbidities",
                    "requirements": [
                        {
                            "requirement_type": "impact on treatment",
                            "expected_value": "precluding locally ablative therapies"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.",
            "criterions": [
                {
                    "exact_snippets": "History of treatment related toxicities that limit or prohibit application of locally ablative therapies.",
                    "criterion": "treatment related toxicities",
                    "requirements": [
                        {
                            "requirement_type": "impact",
                            "expected_value": "limit or prohibit application of locally ablative therapies"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Progressing intracranial lesions.",
            "criterions": [
                {
                    "exact_snippets": "Progressing intracranial lesions",
                    "criterion": "intracranial lesions",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}